Journal
CELLS
Volume 10, Issue 2, Pages -Publisher
MDPI
DOI: 10.3390/cells10020329
Keywords
MDSC; ovarian cancer; survival; therapeutic target; tumor microenvironment
Categories
Funding
- Ministry of Education, Culture, Sports, Science, and Technology of Japan [20K07596]
- Grants-in-Aid for Scientific Research [20K07596] Funding Source: KAKEN
Ask authors/readers for more resources
Myeloid-derived suppressor cells (MDSCs) play a crucial role in ovarian cancer, with increased frequencies associated with poor prognosis. Depletion of MDSCs can significantly inhibit tumor growth and enhance the efficacy of existing anticancer therapies.
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that exhibit immunosuppressive activity. They also directly stimulate tumor cell proliferation, metastasis, and angiogenesis. In ovarian cancer, there are increased numbers of circulating or tumor-infiltrating MDSCs, and increased frequencies of MDSCs are associated with a poor prognosis or an advanced clinical stage. Moreover, in murine models of ovarian cancer, MDSC depletion has shown significant growth-inhibitory effects and enhanced the therapeutic efficacy of existing anticancer therapies. In this review, we summarize the current knowledge on MDSC biology, clinical significance of MDSC, and potential MDSC-targeting strategies in ovarian cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available